Related Experiment Video
Updated: Jun 17, 2025
10:28
Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
Published on: January 22, 2018
11.1K
Targeting the FGFR Pathway in Patients with Advanced Solid Tumors
Chadi Hage Chehade1, Zeynep Irem Ozay1, Neeraj Agarwal1
1Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah.
Summary
Debio 1347 demonstrated limited antitumor effects in advanced solid tumors. Transcriptome analysis revealed insights into FGFR fusion-driven tumors, aiding future clinical trial designs.
Area of Science:
- Oncology
- Molecular Biology
- Clinical Pharmacology
Background:
- Fibroblast Growth Factor Receptor (FGFR) pathway dysregulation is implicated in various advanced solid tumors.
- Targeting FGFR is a therapeutic strategy, but understanding tumor response and resistance is crucial.
Purpose of the Study:
- To evaluate the antitumor activity and safety of Debio 1347 in patients with advanced solid tumors.
- To explore the genomic landscape of FGFR fusion-driven tumors using transcriptome-based analysis.
Main Methods:
- Phase II FUZE clinical trial.
- Administration of Debio 1347 to patients with advanced solid tumors.
- Transcriptome-based genomic analysis of tumor samples.
Main Results:
- Debio 1347 exhibited limited overall antitumor activity.
- The drug was generally well-tolerated, with manageable toxicity.
- Transcriptome analysis provided insights into the genomic characteristics of FGFR fusion-driven tumors.
Conclusions:
- Debio 1347 showed modest efficacy in this patient population.
- Genomic insights from transcriptome analysis can inform future FGFR-targeted therapy development and resistance studies.
Related Concept Videos
02:38Mitogens and the Cell Cycle
6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
01:16TGF - β Signaling Pathway
7.3K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.3K
03:03mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K